Evidence map›Paper›PMID 38396013›Full record

ArticleTranslational psychiatry2024

Effect of antipsychotic drugs on group II metabotropic glutamate receptor expression and epigenetic control in postmortem brains of schizophrenia subjects.

Jon DelaCuesta-Barrutia, Oihane Martínez-Peula, Guadalupe Rivero, Jon A Santas-Martín, Eva Munarriz-Cuezva, Iria Brocos-Mosquera, Patricia Miranda-Azpiazu, Rebeca Diez-Alarcia, Benito Morentin, William G Honer and 3 more

Open access · goldAbstract read
In one paragraph

Article in Translational psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Jon DelaCuesta-BarrutiaDepartment of Pharmacology, University of the Basque Country, UPV/EHU, Leioa, Spain.
Oihane Martínez-PeulaDepartment of Pharmacology, University of the Basque Country, UPV/EHU, Leioa, Spain.
Guadalupe RiveroDepartment of Pharmacology, University of the Basque Country, UPV/EHU, Leioa, Spain.ORCID 0000-0002-2537-4047
Jon A Santas-MartínDepartment of Pharmacology, University of the Basque Country, UPV/EHU, Leioa, Spain.
Eva Munarriz-CuezvaDepartment of Pharmacology, University of the Basque Country, UPV/EHU, Leioa, Spain.ORCID 0000-0003-1943-3642
Iria Brocos-MosqueraDepartment of Pharmacology, University of the Basque Country, UPV/EHU, Leioa, Spain.
Patricia Miranda-AzpiazuDepartment of Pharmacology, University of the Basque Country, UPV/EHU, Leioa, Spain.
Rebeca Diez-AlarciaDepartment of Pharmacology, University of the Basque Country, UPV/EHU, Leioa, Spain.ORCID 0000-0002-0806-9825
Benito MorentinBiocruces Bizkaia Health Research Institute, Barakaldo, Spain.
William G HonerDepartment Psychiatry, University of British Columbia, Vancouver, BC, Canada.
Luis F CalladoDepartment of Pharmacology, University of the Basque Country, UPV/EHU, Leioa, Spain.ORCID 0000-0001-9941-012X
Amaia M ErdozainDepartment of Pharmacology, University of the Basque Country, UPV/EHU, Leioa, Spain.
Alfredo Ramos-MiguelDepartment of Pharmacology, University of the Basque Country, UPV/EHU, Leioa, Spain. alfredo.ramos@ehu.eus.ORCID 0000-0001-6259-1836
University of the Basque Country · ESBioCruces Health research Institute · ESUniversity of British Columbia · CA

Funding

Eusko Jaurlaritza (Basque Government) BIO22/ALZ/002Eusko Jaurlaritza (Basque Government) IT1512/22Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (Spanish Agencia Estatal de Investigación) PID2022-137848OB-I00Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (Spanish Agencia Estatal de Investigación) RTI2018-094414-A-I00Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (Spanish Agencia Estatal de Investigación) RYC-2016-19282
6 · The paper itself

Abstract

Antipsychotic-induced low availability of group II metabotropic glutamate receptors (including mGlu

Indexed as

Antipsychotic AgentsReceptors, Metabotropic GlutamateSchizophreniaAnimalsBrainEpigenesis, GeneticHumansRNA, MessengerAntipsychotic AgentsReceptors, Metabotropic GlutamateRNA, Messenger

Identifiers

PMID38396013
PMCPMC10891050
OpenAlexW4392099479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.